0.23
-0.0109(-4.51%)
Currency In USD
| Previous Close | 0.24 |
| Open | 0.27 |
| Day High | 0.27 |
| Day Low | 0.23 |
| 52-Week High | 2.34 |
| 52-Week Low | 0.22 |
| Volume | 19.67M |
| Average Volume | 1.47M |
| Market Cap | 9.64M |
| PE | -0.48 |
| EPS | -0.48 |
| Moving Average 50 Days | 0.32 |
| Moving Average 200 Days | 0.64 |
| Change | -0.01 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $13.14 as of December 31, 2025 at a share price of $0.23. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $369.5 as of December 31, 2025 at a share price of $0.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
GlobeNewswire Inc.
3 hours ago
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Dec 16, 2025 9:05 PM GMT
HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pote
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Dec 15, 2025 1:00 PM GMT
HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pote